Characteristic Electrocardiographic Manifestations in Patients With COVID-19

He, Jiawei; Wu, Bo; Chen, Yaqin; Tang, Jianjun; Liu, Qiming; Zhou, Shenghua; Chen, Chen; Qin, Qingwu; Huang, Kang; Lv, Jianlei; Chen, Yan; Peng, Daoquan

doi:10.1016/j.cjca.2020.03.028

Cited by 100 publications

(111 citation statements)

References 4 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…COVID-19 complicated by cardiovascular injury may indirectly be reflected by ECG changes. ECG abnormalities including STsegment elevation and multifocal ventricular tachycardia have been reported in patients with COVID-19 [71]. Also, medications are currently used empirically to treat COVID-19 may have side effects and drug interactions, e.g., chloroquine and hydroxychloroquine are known to prolong the QT interval which can potentially lead to fatal side effects [72].…”

Section: A Electrocardiogram For Monitoring Cvd and Covid-19 Patientsmentioning

confidence: 99%

Wearable Sensing and Telehealth Technology with Potential Applications in the Coronavirus Pandemic

Ding

Clifton

et al. 2021

IEEE Rev. Biomed. Eng.

205

155

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has emerged as a pandemic with serious clinical manifestations including death.A pandemic at the large-scale like COVID-19 places extraordinary demands on the world's health systems, dramatically devastates vulnerable populations, and critically threatens the global communities in an unprecedented way. While tremendous efforts at the frontline are placed on detecting the virus, providing treatments and developing vaccines, it is also critically important to examine the technologies and systems for tackling disease emergence, arresting its spread and especially the strategy for diseases prevention. The objective of this article is to review enabling technologies and systems with various application scenarios for handling the COVID-19 crisis. The article will focus specifically on 1) wearable devices suitable for monitoring the populations at risk and those in quarantine, both for evaluating the health status of caregivers and management personnel, and for facilitating triage processes for admission to hospitals; 2) unobtrusive sensing systems for detecting the disease and for monitoring patients with relatively mild symptoms whose clinical situation could suddenly worsen in improvised hospitals; and 3) telehealth technologies for the remote monitoring and diagnosis of COVID-19 and related diseases. Finally, further challenges and opportunities for future directions of development are highlighted.

show abstract

Section: A Electrocardiogram For Monitoring Cvd and Covid-19 Patientsmentioning

confidence: 99%

Wearable Sensing and Telehealth Technology with Potential Applications in the Coronavirus Pandemic

Ding

Clifton

et al. 2021

IEEE Rev. Biomed. Eng.

205

155

View full text Add to dashboard Cite

show abstract

“…Sinus tachycardia is the most common rhythm disturbance reported in patients with COVID-19. Moreover, a variety of other rhythm disorders and electrocardiographic alterations have been reported in patients with COVID-19 such as supraventricular tachycardia [62,63], ventricular tachycardia, first-degree atrioventricular block (AVB), temporary second-degree AVB, reversible complete heart block, generalized STelevation masquerading ST-elevation myocardial infarction (STEMI), triangular-type ST-elevation myocardial infarction type 2, S1Q3T3 pattern mimicking acute pulmonary embolism, non-specific ST and T wave changes, diffuse U waves in the presence of a QTc of 0.45 ms, and pulseless electrical activity [63,75].…”

Section: Spectrum Of Newly Developed Arrhythmias and Electrocardiogramentioning

confidence: 99%

Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool

et al. 2020

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) pandemic has drastically affected global health. Despite several studies, there is yet a dearth of data regarding the mechanisms of cardiac injury, clinical presentation, risk factors, and treatment of COVID-19-associated cardiovascular disease. This systematic review and meta-analysis is aimed at defining the clinical, electrocardiographic, and pathologic spectrum of cardiovascular disease (CVD), frequency of elevated cardiac and inflammatory biomarkers, and their frequency and relationship with severity of the disease and mortality in COVID-19 patients and to develop a triage risk stratification tool (TRST) that can serve as a guide for the timely recognition of the high-risk patients and mechanism-targeted therapy. We conducted an online search in databases of PubMed and Embase to identify relevant studies. Data selection was in concordance with PRISMA guidelines. Results were presented as pooled frequencies, odds ratio, standardized mean difference (SMD), and forest and funnel plots. Results: We gathered a total of 54 studies and included 35 of them in our meta-analysis. Acute cardiac injury occurred in more than 25% of cases, mortality was 20 times higher, and admission to intensive care unit increased by 13.5 times. Hypertension was the most common pre-existing comorbidity with a frequency of 29.2%, followed by diabetes mellitus (13.5%). The deceased group of patients had higher cardiac and inflammatory biomarkers, with statistically significant SMD, compared with survivors. Pediatric patients were predominantly mildly affected. However, less frequently, the presentation was very similar to Kawasaki disease or Kawasaki shock syndrome. This latter presentation hass been called as multisystem inflammatory syndrome in children (MIS-C). Conclusions: There is a wide spectrum of cardiac involvement in COVID-19 patients, and hence a Triage Risk Stratification Tool can serve as a guide for the timely recognition of the high-risk patients and mechanism-targeted therapy.

show abstract

“…Temporary occurrence of S1Q3T3 and subsequent transient, nearly complete A-V block may reflect transient pulmonary artery hypertension secondary to trachea secretive obstruction, which may cause extensive small pulmonary artery compression [ 29 ]. The development of ST-elevation and ventricular tachycardia can have multiple triggers, such as hypoxia, hydroxychloroquine-induced arrhythmias, among others [ 29 ]. A study carried out by Wang et al reported a 16.7% incidence of arrhythmia, more so in the intensive care unit (ICU) admissions [ 1 ].…”

Section: Signs and Symptoms Of Cardiovascular Injurymentioning

confidence: 99%

Cardiology and COVID-19: do We have Sufficient information?

et al. 2020

View full text Add to dashboard Cite

Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2, which originated in Wuhan (China), transformed into a worldwide pandemic. The short span associated with the spread of the virus and its varied manifestations presents a steep learning curve for many clinicians on the front-line of treatment. Cardiology is one such affected area. This paper details the signs and symptoms of cardiovascular disease resulting from COVID-19, including its proposed pathophysiology, signs and symptoms, treatments and outcomes under investigation. The consensus is that COVID-19 patients with cardiovascular injury have a shorter duration from symptom onset to deterioration, higher mortality and higher prevalence in older populations. Diagnosis and intervention for patients with underlying cardiovascular comorbidities is critical.

show abstract

Characteristic Electrocardiographic Manifestations in Patients With COVID-19

Cited by 100 publications

References 4 publications

Wearable Sensing and Telehealth Technology with Potential Applications in the Coronavirus Pandemic

Wearable Sensing and Telehealth Technology with Potential Applications in the Coronavirus Pandemic

Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool

Cardiology and COVID-19: do We have Sufficient information?

Contact Info

Product

Resources

About